Mr. David Adelman reports

VESALIUS LONGEVITY LABS APPOINTS HARVEY SPEVAK AS CHAIRMAN TO ACCELERATE GLOBAL GROWTH AND BRAND DEVELOPMENT

Vesalius Longevity Labs Inc. has appointed Harvey Spevak as chairman of its board of directors, effective Nov. 13, 2026. The appointment follows a $6.5-million (U.S.) financing led by Mr. Spevak, who brings a globally recognized leader in the wellness space to Vesalius as interest in longevity and pro-active health continues to accelerate.

Mr. Spevak is an investor, a visionary leader in global wellness, lifestyle and hospitality, and chairman of Equinox Group. With more than three decades of experience building and scaling iconic consumer brands, he is recognized for his brand-focused, consumer-centric approach to innovation, growth and long-term value creation. As chairman, he will help guide Vesalius's strategic direction, brand development and global expansion at the intersection of health care delivery and longevity science.

Vesalius supplies peptide products to a significant network of health care providers across key global markets, supporting their practices with product fulfilment and provider education. Continuing to scale its provider-led platform globally, the company enters this next phase with momentum as the broader peptide therapeutics market is projected to reach $295-billion (U.S.) by 2033, up from $141-billion (U.S.) in 2025, according to Grand View Research.

Recently, the company announced an exclusive manufacturing partnership with FDA-registered (U.S. Food and Drug Administration) Celularity at Celularity's facility in Florham Park, N.J. Celularity operates a cGMP (current good manufacturing practice), Grade D/ISO 8, AABB-certified manufacturing facility. The company has now established an active, first-of-its-kind, U.S. made-in-the-USA peptide manufacturing for its Peptual-branded APIs (active pharmaceutical ingredients) (excluding any GLP-type products).

"I believe longevity represents one of the most exciting opportunities in health and wellness over the coming decade," said Mr. Spevak, chairman of Vesalius. "Vesalius has an ambitious vision for building a differentiated global platform. I'm excited to work with the board and management team, bringing my experience in building consumer-focused brands, driving innovation and creating long-term value to help shape the company's next phase of growth."

Mr. Spevak joins fellow board members with expertise in health, finance, media and global consumer businesses, including: David Adelman, co-owner of the Philadelphia 76ers and New Jersey Devils; Kevin Mayer, executive chairman and founder of Smash Capital, co-chief executive officer of Candle Media and former CEO of TikTok, who led Disney+, Hulu and ESPN+ at The Walt Disney Company; Lee Applbaum, chief marketing officer of Norwegian Cruise Line and former global chief marketing officer of Patron Spirits; Dr. Kevin Serre, PhD, formerly the head of performance for the Canadian Department of Defence (DoD) Special Forces under CANSOFCOM (Canadian Special Operations Forces Command); and James McRoberts, founder of the company and executive chairman of MuseCell Innovations Pte. Ltd.

"On behalf of the board, I am pleased to welcome Harvey as chairman," said Mr. Adelman, director of Vesalius. "He joins a group of directors whose experience across health, finance, media and consumer brands has already helped shape Vesalius into the company it is today. With Harvey leading the board, we are well positioned as Vesalius scales globally."

"Vesalius is well positioned to help shape the future of peptides and longevity, with high-quality products, a growing provider network and significant opportunity to scale," said Mr. Mayer, director of Vesalius. "Our ambition is to build a category-defining brand that earns the trust of providers and patients alike. I have known Harvey for many years; his leadership and strategic vision are exceptionally strong. Harvey has a proven track record of building an iconic brand and transforming an industry, and his leadership will be invaluable as we realize Vesalius's full potential."

Financial adviser

Roth Capital Partners serves as the exclusive financial adviser to Vesalius Longevity Labs.

About Vesalius Longevity Labs Inc.

Vesalius Longevity Labs is a longevity and regenerative health platform focused on peptides, biologics and preventive health care. Vesalius's proprietary ecosystem is designed to connect health care providers with trusted, compliant pharmacies and support the people they serve with access to quality therapies, education and partnerships.

Through its announced collaboration with Celularity, the company is developing a U.S. final-stage manufacturing and supply platform for its Peptual-branded peptide APIs for domestic and international compounding supply chains in accordance with local laws and regulations. Vesalius's vision is to deliver on the promise of longevity by enabling the future of personalized health and wellness.

We seek Safe Harbor.